Backed by General Catalyst and GV.
About the role
Parabilis is scaling toward a commercial future, and the systems our teams rely on have too often grown one step at a time rather than being designed as coherent wholes. The Enterprise Solutions Architect exists to change that. This is a senior, cross-functional design and delivery role that partners with business teams, internal technology functions, and external vendors to evaluate, design, and deploy streamlined, well-architected workflows and the data foundations beneath them.
What they're looking for
- 7+ years of demonstrated experience designing and deploying cross-functional business systems and workflows end to end, not just implementing point tools
- Bachelor’s degree in computer systems or related field a plus
- Demonstrated experience designing and deploying cross-functional business systems and workflows end to end, not just implementing point tools
- A track record of personally running multi-workstream implementations to completion — planning, sequencing, risk and issue management, and go-live — without a dedicated project manager alongside you
- Strong systems thinking and data-architecture skills: the ability to model how processes, systems, and data should fit together across teams
- A track record of partnering with non-technical stakeholders to elicit needs, negotiate scope and trade-offs, and drive alignment and adoption without holding line authority over them
More about this role
About Parabilis Medicines
Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact. For more information, visit www.parabilismed.com or follow us on LinkedIn .
Parabilis is scaling toward a commercial future, and the systems our teams rely...
Browse similar: Startup jobs · Remote jobs